Karishma
Metformin – a new frontier in skin cancer pharmacotherapy
Journal title : Yemen Journal of Medicine
Publisher : Mansa STM Publishers
Online ISSN : 2583-4614
Page Number : 65-78
Journal volume : 04
Journal issue : 01
85 Views Reviews Article
Metformin, a widely prescribed biguanide for type 2 diabetes, has emerged as a promising candidate in skin cancer therapy due to its diverse anticancer mechanisms. Beyond its glucoselowering effects, metformin inhibits key oncogenic pathways, including the PI3K/AKT/mTOR and insulin/IGF-1 signaling pathways, activates AMP-activated protein kinase, and disrupts mitochondrial complex I function. These mechanisms are presumed to contribute to metformin's antiproliferative, pro-apoptotic, and anti-inflammatory effects, potentially reducing tumor growth and metastasis in melanoma and non-melanoma skin cancers. Predictive molecular docking studies reveal that metformin interacts with critical proteins in melanoma pathophysiology. Against PI3K/mTOR (PDB: 5OQ4), PTPN2 (PDB: 7UAD), and TRIP13 (PDB: 5VQA), metformin exhibited docking scores of -4.4, -4.6, and -5.6 kcal/mol, respectively, interacting via hydrogen bonding with residues such as ASP-836, ASP-964 (5OQ4), ASP-50 (7UAD), and SER-187, SER-138 (5VQA). Compared to standard inhibitors, PQR309 (-9.4 kcal/mol), ABBV-CLS-484 (-7.5 kcal/mol), and ATP (-10.8 kcal/mol), metformin displayed moderate binding affinity, suggesting potential but weaker inhibition of these targets. Preclinical and clinical studies support metformin's potential to reduce skin cancer risk, particularly in diabetic patients. However, challenges regarding bioavailability, optimal dosing, and patient selection persist, necessitating further investigation. Therefore, given its affordability, safety, and multitargeted action, metformin represents an attractive candidate for repurposing in skin cancer pharmacotherapy. Focusing future research on optimizing its therapeutic application, refining drug combinations, and identifying biomarkers would enhance clinical outcomes.
Article DOI & Crossmark Data
DOI : https://doi.org/10.63475/yjm.v4i1.0091
Article Subject Details
Article Keywords Details
Article File
Full Text PDFMore Article by Karishma
The internal medicine residency program at hamad medical corporation (hmc) is accredited by the accreditation council for graduate medical education–international (acgme-i). upon c...
The city that never sleeps, a vibrant tapestry of dense neighborhoods and relentless energy, has long grappled with the pervasive challenge of air pollution. the very dynamism that...
Background: acute and chronic heart or kidney failure affect each other in cardiorenal syndromes (crs). in crs, hemodynamic and non-hemodynamic changes occur, causing acute or prog...
Dignity therapy (dt) is an evidence-based psychotherapeutic approach originally designed to alleviate emotional and existential distress in patients with terminal illnesses. while ...